It now seems possible to vaccinate against cancer
Medical researchers are pursuing two distinct strategies to vaccinate against cancer. One approach prevents infections that lead to malignancy, such as HPV vaccinations which Dr. Daniel Griffin states reduce head and neck cancer cases by 70%. The second approach utilizes personalized mRNA therapies, including a Moderna trial combining mRNA with Keytruda to stop melanoma from returning. The primary goal is to transition these treatments from clinical trials into general public healthcare access.
What changed
No new information regarding cancer vaccinations was provided in the latest source material.
Live updates
-
Cancer Vaccine Research Focuses on mRNA and Infection Prevention
Medical researchers are pursuing two distinct strategies to vaccinate against cancer. One approach prevents infections that lead to malignancy, such as HPV vaccinations which Dr. Daniel Griffin states reduce head and neck cancer cases by 70%. The second approach utilizes personalized mRNA therapies, including a Moderna trial combining mRNA with Keytruda to stop melanoma from returning. The primary goal is to transition these treatments from clinical trials into general public healthcare access.
Why it matters
Cancer vaccines differ from traditional vaccines by either stopping a viral trigger or training the immune system to recognize existing tumor cells. These developments represent a shift toward precision medicine. Success in these trials would change the standard of care for preventable and recurring cancers.
What is confirmed
- HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin.
- Moderna is testing a personalized mRNA therapy combined with Keytruda to prevent melanoma from returning.
What to watch next
- Results from Moderna's mRNA melanoma trials
- Regulatory approval for personalized mRNA cancer therapies
confidence 100%Sources used for this update (4)
- www.today.com — Is There a Summer COVID Surge? With Cases Rising in Nearly Every State, Watch for These Symptoms
- jen.jiji.com — Vuelta a España, today 17th stage: schedule, route and where to watch it
- www.commondreams.org — Israel/OPT: Settlement trade restrictions must be followed by further concrete measures to end Israel’s unlawful occupation and apartheid
- www.commondreams.org — Federal Appeals Court Hears Baseless Challenge to the Abortion Pill Mifepristone — Again
-
Cancer Vaccination Research Focuses on mRNA and Preventative HPV Therapies
Researchers are developing cancer vaccinations through two primary paths: preventing infections that cause cancer and creating personalized mRNA therapies. HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin. Moderna is testing a personalized mRNA therapy combined with Keytruda to prevent melanoma from returning. The current medical objective is to move these preventative and personalized treatments from clinical trials into general public use.
Why it matters
Preventing viral infections can directly lower the incidence of specific cancers. Combining mRNA technology with existing immunotherapy offers a path toward personalized cancer prevention.
What is confirmed
- HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin.
- Moderna has shown promise in preventing melanoma recurrence when used with Keytruda.
What to watch next
- Results from wider public availability trials for personalized mRNA therapies
- Updated data on the long-term efficacy of HPV vaccines in reducing head and neck cancers
confidence 100%Sources used for this update (4)
- www.healthline.com — FDA Approves 4 Updated COVID-19 Vaccines for 2026–2027 Season
- jen.jiji.com — Indonesia, Anak Krakatau volcano erupts: four airports closed, disruptions for over 270,000 passengers
- www.aol.com — 80 Painful But Necessary Stories Of Going No Contact With A Parent
- www.bbc.co.uk — New videos of man in 9/11 lawsuit reveal extremist links
-
Personalized mRNA Vaccines Offer New Hope for Cancer Prevention
Medical specialists are observing broad data showing how infectious disease prevention directly lowers specific cancer rates, complemented by previous trials for personalized mRNA therapies. A study of 1.4 million patients indicates that HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin. Moderna has demonstrated promise in preventing melanoma recurrence when combined with Keytruda. Clinical focus currently centers on transitioning these personalized and preventative therapies into wider public availability.
Why it matters
Cancer vaccines represent a major shift from traditional treatments toward targeted prevention and personalized medicine. Clinical trials combining mRNA technology with existing immunotherapies aim to lower recurrence rates for aggressive malignancies like melanoma. Public health data linking HPV inoculations to significantly reduced head and neck cancer rates further validates the broader strategy of utilizing vaccines against cancer-linked conditions.
What is confirmed
- A study of 1.4 million patients shows that HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin.
- Moderna has shown promise in preventing melanoma recurrence when used with Keytruda.
What to watch next
- Broader public availability of personalized and preventative cancer therapies
- Further clinical trial results combining mRNA therapies with Keytruda for melanoma recurrence
confidence 100%Sources used for this update (5)
- jen.jiji.com — Earthquake today in Cosenza, magnitude 3.7 tremor: felt throughout the province
- sg.news.yahoo.com — Great British Bake Off spin-off revamp as Extra Slice is axed - with Jo Brand and Tom Allen exiting
- jen.jiji.com — Ukraine-Russia, Trump: "I have a peace proposal". Witkoff and Kushner first to Putin and then to Zelensky
- jen.jiji.com — Formula 1, today Monza GP qualifying - Live
- www.usatoday.com — Personalized mRNA cancer vaccines offer new hope. We explain
-
HPV Vaccines Reduce Head and Neck Cancer Cases by 70%
A study of 1.4 million patients shows that HPV vaccinations reduce head and neck cancer cases by 70%, according to Dr. Daniel Griffin. This adds to the growing evidence for cancer prevention via vaccination, complementing previous trials for personalized mRNA therapies. While Moderna has shown promise in preventing melanoma recurrence when used with Keytruda, medical specialists are now seeing broad data on how infectious disease prevention directly lowers specific cancer rates. The current clinical focus remains on moving these personalized and preventative therapies into wider public availability.
Why it matters
Vaccine technology is shifting from treating existing tumors to preventing their development. Personalized mRNA vaccines target specific patient mutations, while HPV shots target the viruses that cause various cancers. These developments aim to increase long-term cancer-free survival rates across different patient populations.
What is confirmed
- A study of 1.4 million patients found HPV shots cut head and neck cancer cases by 70%
- A personalized mRNA vaccine used with Keytruda prevents melanoma from returning or spreading in high-risk patients after surgery
What to watch next
- Clinical trial results for Moderna cancer vaccines moving into general clinical settings
- Data on the wide-scale availability of personalized mRNA therapies
confidence 90%Sources used for this update (9)
- www.briefs.co — France Faces Budget Crisis as Political Gridlock Threatens Stability
- jen.jiji.com — Mario Calabresi leaves Chora Media: towards candidacy for mayor of Milan
- jen.jiji.com — Russia, Tajani: "Possible attempts to influence elections. Russian assets to finance Kyiv? Not against, but it risks a boomerang"
- news.err.ee — Who is Estonia's new President Ülle Madise and what does she think of life?
- ca.style.yahoo.com — 39 Infuriating Stories About MILs Who Can't Survive Without Making Everyone Suffer (August Edition)
- jen.jiji.com — Milan, Formigoni: "Calabresi? For the center-right, the game remains open, moderates are not easily fooled"
- jen.jiji.com — US Open, today Cobolli-Schoolkate: schedule, head-to-head, and where to watch it on TV
- www.ilfoglio.it — Pseudoscience can kill, but it causes even greater harm when it corrupts institutions
- finance.biggo.com — Dr. Daniel Griffin: HPV Shots Cut Head and Neck Cancer Cases by 70% in 1.4 Million-Patient Study
-
Moderna cancer vaccine trials prompt calls for faster personalized therapy
A positive trial for a Moderna cancer vaccine provides hope for treating patients, though researchers emphasize that more work is required to move these effective vaccines into clinical settings. This follows previous findings that a personalized mRNA vaccine, used alongside Keytruda, prevents melanoma from spreading or returning in high-risk patients after surgery. While these results show potential for long-term cancer-free survival, the current focus is on accelerating the development of personalized therapies to make them widely available to the public.
Why it matters
The development of these mRNA vaccines follows a decade of logistical and pandemic-related challenges. This technology aims to remodel the immune system to generate T cells that can eradicate or slow tumor growth.
What is confirmed
- A personalized mRNA vaccine developed by Moderna and Merck prevents melanoma from returning or spreading in high-risk patients when paired with Keytruda.
- Positive trials for the Moderna cancer vaccine show promise for treating people with cancer.
What to watch next
- Clinical trial results for personalized mRNA therapies beyond melanoma
- Regulatory approval timelines for the Moderna and Merck vaccine combination
confidence 90%Sources used for this update (9)
- inews.co.uk — Hegseth’s escalating purge is rocking the US military
- inews.co.uk — CIA chief’s secret trip to Moscow shows Putin’s threat to Nato is deadly serious
- www.yahoo.com — Why we just can’t shake our obsession with curses
- inews.co.uk — Putin is up to something – it will be dirty and deniable
- inews.co.uk — Young people with anxiety and ADHD to be offered taxpayer-funded jobs at Boots
- www.yahoo.com — Rescue Kitten Clings to Dog Like She’s Her Mama & It’s Exactly What They Both Need
- inews.co.uk — The surprise bonus benefits of four common vaccines
- apnews.com — Live updates: Death toll rises in Nepal-China border disaster as lake poses new flood threat
- www.nature.com — The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
-
Moderna and Merck vaccine reduces melanoma recurrence risk
An experimental personalized mRNA vaccine developed by Moderna and Merck prevents melanoma from returning or spreading in high-risk patients. When paired with the drug Keytruda, the treatment helps patients stay cancer-free longer following surgery. This result follows a decade of development characterized by logistical hurdles and pandemic-era obstacles. Separate research into mRNA molecules also shows potential for remodeling the immune system to generate T cells capable of slowing or eradicating tumor growth.
Why it matters
Melanoma is a high-risk skin cancer prone to recurrence after surgical removal. Personalized vaccines tailor treatment to the individual's specific cancer markers to trigger a targeted immune response. This shift toward mRNA-based oncology represents a move from general chemotherapy toward precision medicine.
What is confirmed
- Moderna and Merck developed an experimental vaccine that prevents melanoma from returning or spreading in high-risk individuals.
- A personalized mRNA vaccine used alongside Keytruda may prevent skin cancer recurrence after surgery.
Still unconfirmed
- Researchers generated T cells using mRNA molecules that can slow tumor growth or eradicate tumors.
What to watch next
- Peer review of the large clinical trial data
- Regulatory approval filings for the personalized vaccine
- Results from expanded trials targeting other cancer types
confidence 90%Sources used for this update (8)
- medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
- www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
- en.protothema.gr — What K.M. & Tsipras say about the elections, the phantom investor and the crème de la crème, bonuses at Astieras & shipowners selling tankers
- www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
- www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
- www.yahoo.com — Baby Girl Names From The '70s That Are Making A Comeback
- www.technologyreview.com — Amping up T cells to target cancer
- www.yahoo.com — Please stop putting AI-generated food on the menu
-
Cancer vaccination shows promise with Moderna's melanoma vaccine
Moderna's melanoma vaccine, developed with Merck, has shown promising results in a large trial, potentially paving the way for cancer vaccination. The vaccine, designed to prevent skin cancer recurrence, has sparked optimism about its effectiveness. This development could lead to a new approach in cancer treatment.
Why it matters
The fight against cancer has seen significant advancements, with vaccination emerging as a potential strategy. Moderna's success with its COVID-19 vaccine has translated to cancer research, with the company's melanoma vaccine demonstrating encouraging results. The vaccine's ability to prevent cancer recurrence could revolutionize treatment options.
What is confirmed
- Moderna shares surged after announcing the success of their melanoma vaccine in a large trial.
- The melanoma vaccine was developed in partnership with Merck.
- The vaccine aims to prevent skin cancer from recurring in patients.
Still unconfirmed
- Investors thought Moderna was left for dead before the cancer breakthrough.
What to watch next
- Further trial results for Moderna's melanoma vaccine
- FDA approval process for the vaccine
- Potential applications of the vaccine in other types of cancer
confidence 85%Sources used for this update (9)
- baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
- Reuters — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
- The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
- CNN — Moderna, Merck breakthrough could usher in wave of cancer vaccines
- The Washington Post — Opinion | A cancer vaccine would be a miracle of science — and the free market
- The Economist — It now seems possible to vaccinate against cancer
- WSJ — Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough.
- WCAX — New melanoma vaccine could shed light on Vermont’s high rates
- Bloomberg.com — Why Moderna’s Cancer Vaccine Is a Breakthrough for mRNA